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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effect of screening mammography for breast cancer on overdiagnosis in women aged 40 years and older at average risk of
breast cancer.
B A C K G R O U N D
Description of the condition
Breast cancer is the most common cancer in women worldwide
and a leading cause of cancer death (Ferlay 2015). During the
late twentieth century, screening mammography was introduced
in high-income countries on the evidence that it reduced breast
cancer mortality, without adequate consideration or knowledge of
potential harms. During this time there was an increase in breast
cancer incidence in women aged between 50 to 69 years. This was
partly due to changes in risk factors such as alcohol intake, re-
productive factors, obesity and hormone therapy use (Bray 2004;
Jemal 2010); but also, as has now become apparent, because of
widespread uptake of screeningmammography and resulting over-
diagnosis. In the context of cancer screening, overdiagnosis is the
detection of cancer by screening that would never cause symptoms
or harms in the absence of screening (Baker 2014; Marcus 2015;
Welch 2010). Overdiagnosis involves the interaction between the
biology of preclinical cancer and competing risks for mortality.
Thus it can occur through the detection of non-progressive pre-
clinical breast cancer, or through the detection of progressive, pre-
clinical cancer in women with limited life expectancy.
Overdiagnosis is now acknowledged as the major harm of screen-
ing mammography (Independent UK Panel on Breast Screening
2012). It should not be confused with a false positive result: when
a screening test detects an abnormality but with further investi-
gation, no cancer is found. By contrast, overdiagnosis is a can-
cer diagnosis which is correct according to contemporary profes-
sional standards for pathology reporting and classification. As it
is currently not possible to identify individuals who will benefit
or be harmed by early detection and treatment, almost all cancer
patients are offered treatment. Thus, to the extent that overdiag-
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nosis of cancer occurs, it leads to overtreatment (Brawley 2017;
Independent UK Panel on Breast Screening 2012) - unnecessary
surgery, radiotherapy and other adjuvant therapy - that will not
benefit individuals but may harm them through life-long physical
and psychological consequences that can impact quality of life and
life expectancy (Esserman 2014). As such, there is a scientific and
public health imperative to establish the frequency of overdiagno-
sis. This is the evidence gap this review seeks to address.
As for all healthcare interventions, the benefit of cancer screening
must be weighed against the potential harm. An earlier Cochrane
Review of screening mammography for breast cancer quantified
the benefit (Gøtzsche 2013). The review authors estimated that
breast cancer-specific mortality was reduced by approximately
19% in randomised trials where women were invited to screen-
ing. They noted, however, that there was no significant benefit
when the analysis was restricted to the best quality trials. In the
review, they identified overdiagnosis and overtreatment as harms
of screening that should be weighed against the benefit, but only
assessed randomised controlled trials (RCTs).
Although early detection of breast cancer may lead to a mortality
benefit, overdiagnosis is an unintended but inevitable risk of trying
to detect pre-symptomatic cancer in age groups at significant risk
of death from other causes. Thus, if women wish to be screened
because they value the opportunity to reduce their risk of dying
from breast cancer, that inevitably entails accepting an addition
risk of diagnosis and treatment, including the risk of overdiag-
nosis and overtreatment. If screening catches many slow-growing
cancers that would not cause symptoms or death, then the harms
may outweigh the health benefits, both for populations and for
individual women. Therefore, establishing the frequency of over-
diagnosis is critically important to determine whether the net ben-
efit justifies the resources required for screening, and to provide
the best information possible to help healthy women weigh up
the potential benefit versus the potential harm of participating in
breast cancer screening.
To reliably estimate the effect of screening on breast cancer inci-
dence we look to randomised controlled trials. Of the nine large
trials undertaken, only three were suitable to accurately measure
overdiagnosis (Miller 2000; Miller 2002; Zackrisson 2006). An
independent meta-analysis of these trials suggests that 19% of
screened women who are diagnosed with breast cancer experience
overdiagnosis (Independent UK Panel on Breast Screening 2012).
The authors of this analysis, however, emphasised the uncertainty
around this estimates due to the scarcity of data, the small number
of cases and the fact that not all women were followed to the end
of their lives.
Of particular concern is that these three trials were undertaken be-
tween 1977 and 1988. Contemporary screening mammography
is more sensitive than film, and the incidence of ductal carcinoma
in situ (DCIS) has increased because of screening (Ernster 1996;
Kerlikowske 2010; Van Steenbergen 2009; Virnig 2009) without
a corresponding decrease in invasive breast cancer (Jacklyn 2017a;
Jørgensen 2017; Sørum 2010). There are also differences between
the screening mammography trials and international programmes
in target age, screening technology, intervals, number of views and
readers, and follow-up time. An analysis of non-randomised stud-
ies would have the advantage of evaluating current trends in breast
cancer incidence and help quantify overdiagnosis in screening pro-
grammes to better inform individuals, clinical practice and policy.
More contemporary estimates of overdiagnosis from non-ran-
domised studies range from 0% up to 54% (Biesheuvel 2007;
CTFPHC 2011; Myers 2015; Nelson 2016; Puliti 2011). The
variation in these results may represent discrepancies in the choice
of denominator as well as methodological differences, such as al-
lowance for lead-time and volunteer bias (Biesheuvel 2007; de
Gelder 2011).
Lead time is the amount of time screening advances the diagnosis
of cancer. Lead time bias inflates survival statistics when early de-
tection of disease does not extend lifetime, it only leads to an earlier
diagnosis. Allowing for lead time is essential in studies of screening
because it causes a temporary increase in cancer incidence which
is a prerequisite for the intervention to work. The challenge is to
separate the desirable increase in incidence due to advancement of
the time of diagnosis from the undesirable increase due to over-
diagnosis.
Volunteer bias (a type of selection bias) refers to the observation
that people who choose to participate in screening tend to be
different from those who do not volunteer. Women who choose
to screen are generally healthier, have better health behaviours and
their outcomes tend to be better because of this (Falk 2013; Puliti
2012). They may also represent the worried well; that is, people
who do not have symptoms but are at higher risk of breast cancer
(Moss 2006). Good quality studies such as randomised controlled
trials help to avoid these biases, but they are difficult to control
for in non-randomised studies.
Description of the intervention
Screening mammography involves an x-ray of both breasts (one-
view or two-view, using film or digital mammography) in asymp-
tomatic women to detect a suspicious abnormality and classify
them at high or low risk of breast cancer. If a woman has an abnor-
mality detected she may undergo one or a combination of further
investigations such as clinical examination, diagnostic mammog-
raphy, ultrasound and biopsy procedures. Women who receive a
diagnosis of breast cancer are treated with surgery (breast conserv-
ing surgery or mastectomy), and may receive therapies (one of or
a combination of radiotherapy, hormone therapy, chemotherapy,
human epidermal growth factor receptor 2 (HER2) blockade and
other biological therapy).
How the intervention might work
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Screeningmammographyworks via early detection and treatment.
Rather than waiting for symptoms such as a lump to appear be-
fore treating breast cancer, we look for disease before these signs
develop and thus advance in time the diagnosis. By shifting the
incidence to an earlier stage, breast cancer should be more curable
and require less intensive treatment, thereby reducing the inci-
dence of cancers that first present as advanced disease (Morrison
1992). However, international data from non-randomised studies
demonstrate a significant increase in early-stage disease (DCIS and
localised breast cancer), with minimal or no decline in advanced
breast cancer (regional anddistantmetastases) (Autier 2011; Autier
2017; Bleyer 2012; de Glas 2014; Harding 2015; Jacklyn 2017b;
Jørgensen 2017; Kalager 2012; Lousdal 2014). We are finding
that cancers behave in a variable way and do not necessarily lead
to metastases and death (Welch 2010; Zahl 2008). Thus an un-
intended consequence of screening is the detection of preclinical
cancers that are either 1) non-progressive or regressive (Lewison
1976; Zahl 2008) - that is, breast cancers that were never destined
to present clinically or cause harm; or 2) breast cancers which
would have progressed so slowly that women die from other causes
before symptoms would have appeared.
Why it is important to do this review
One of the difficulties in making recommendations about screen-
ing mammography is that the benefits have been more extensively
studied than the harms. The randomised trials were primarily de-
signed to detect a reduction in disease-specific mortality, while
overdiagnosis was generally overlooked. Furthermore, the abso-
lute benefit to harm ratio may be finely balanced or may have be-
come less favourable as treatments for breast cancer have improved
(Birnbaum 2016). At the same time, greater mammographic sen-
sitivity could increase benefit, while at the same time also increas-
ing the harm from overdiagnosis. As the impact of these changes
is unknown, it is increasingly important to carefully quantify the
trade-offs in the current context using both randomised and non-
randomised studies. Further, a recent systematic review of meth-
ods suggested that well-conducted ecological and cohort studies
are the most appropriate approach for quantifying and monitor-
ing overdiagnosis in cancer screening programmes (Carter 2015).
Therefore a detailed and careful assessment of overdiagnosis is
needed to inform current appraisals of screening mammography
and guide decisions of consumers, clinicians and policymakers
when weighing up the benefits and harms. To help provide an
overview of this, we will discuss the outcomes of our analysis in
the context of the existing Cochrane Review of the benefit from
screening (Gøtzsche 2013).
O B J E C T I V E S
To assess the effect of screening mammography for breast cancer
on overdiagnosis in women aged 40 years and older at average risk
of breast cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will identify and evaluate all primary epidemiological studies
that attempt to measure overdiagnosis resulting from screening
mammography. We will include:
• randomised controlled trials, including cluster randomised
controlled trials;
• cohort studies;
• case-control studies; and
• ecological studies.
We will also search for re-analyses of published incidence data that
assess overdiagnosis.
We will exclude the following types of studies:
• systematic reviews that only report or combine quantitative
estimates of overdiagnosis from included study types
(randomised trials, cohort studies, case-control studies and
ecological studies) that quantified overdiagnosis;
• non-systematic reviews;
• modelling studies; and
• pathological or imaging studies.
We have provided reasons for excluding certain study types in
Appendix 1.
Types of participants
Women aged 40 years and older during the active screening period
and at average (background population) risk for breast cancer.
Types of interventions
Exposure
Any form of screening mammography (one-view, two-views, film,
digital).
Comparator
No screening mammography.
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Types of outcome measures
There are different ways to calculate overdiagnosis and different
estimates address different questions. We have found the approach
of the Independent UK Panel on Breast Cancer Screening helpful
(Independent UK Panel on Breast Screening 2012), and thus we
will present several estimates of overdiagnosis using the panel’s
definitions.
Primary outcomes
• The probability of overdiagnosis from the perspective of an
individual woman: the percentage risk of overdiagnosis among
all cancers detected (both screen-detected and interval cancers)
in women invited to screening. This outcome is the preferred
method of the Independent UK Panel, Method C (Independent
UK Panel on Breast Screening 2012). It reflects the probability
that a breast cancer diagnosed during the active screening period
represents overdiagnosis. This measure of overdiagnosis is most
relevant to individual women considering screening
mammography and addresses the question: if I am invited to
attend screening and receive a breast cancer diagnosis, how likely
is it to represent overdiagnosis?
Secondary outcomes
• Relative risk of overdiagnosis: the risk of excess breast
cancer detection due to overdiagnosis in screened women
compared to unscreened women. This answers the question:
what is the percentage increase in risk of a breast cancer diagnosis
in women invited to screening?
• Absolute risk of overdiagnosis: the probability that a woman
invited to screening will be overdiagnosed. This measure answers
the question: for every 1,000 women invited to screening, how
many will be overdiagnosed during the active screening period?
• Percentage risk of overdiagnosis of screen-detected cancers:
the probability that a screen-detected cancer represents
overdiagnosis (method D, Independent UK Panel on Breast
Screening 2012).
• Long-term percentage risk of overdiagnosis: the probability
that a cancer diagnosed during the screening period and for the
remainder of a woman’s lifetime in women invited to screening
will be overdiagnosed (method B, Independent UK Panel on
Breast Screening 2012).
• The effect of screening mammography on the incidence of
early- and advanced-stage breast cancer.
Search methods for identification of studies
Electronic searches
We will use different methods to search for randomised and non-
randomised studies.
When identifying completed and ongoing randomised controlled
trials, wewill look to the reference list of existing systematic reviews
on screening mammography for breast cancer (CTFPHC 2011;
Gøtzsche 2013; Independent UK Panel on Breast Screening 2012;
Nelson 2016). We do not intend to search trial registries as we are
aware of only one ongoing trial (conducted in the UK) that aims
to complete recruitment in 2026 (NCT01081288).
When identifying non-randomised controlled studies, we will
search two databases:
• MEDLINE (via OvidSP; from 1946 to present) (Appendix
2);
• Embase (via OvidSP; from 1974 to present) (Appendix 3).
Searching other resources
Bibliographic searching
We will try to find further studies from reference lists of identified
relevant non-randomised studies, trials and reviews. A copy of the
full article for each reference reporting a potentially eligible study
will be obtained. Where this is not possible, we will attempt to
contact the study authors to provide additional information.
Grey searching
We will search grey literature for reports and conference proceed-
ings in the following databases:
• COS Conference Papers Index through ProQuest;
• Grey Literature Report and Index, The New York Academy
of Medicine;
• Health Services Research Projects in Progress (HSRProj);
• Mednar;
• NIH Research Portfolio Online Reporting Tools
(RePORTER);
• OAlster;
• OpenGrey Repository;
• Papers First;
• ProQuest Dissertations and Theses Global.
Data collection and analysis
We will follow the recommended approach for data collection
and management as documented in the Cochrane Handbook for
Systematic Reviews (Higgins 2011).
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Selection of studies
One review author (GJ) will screen titles and abstracts of all records
retrieved by the searches for relevance. We will also use Robot-
Analyst, a text mining application, to screen for potentially rele-
vant titles and abstracts (Kontonatsios 2017; O’Mara-Eves 2015).
Two review authors (GJ and AB) will independently assess full-
text copies of potentially eligible articles. Studies published as ab-
stracts only will be excluded. We will resolve any discrepancies
through consensus or recourse to a third review author (KB) if
we cannot reach agreement. We will list all studies excluded after
full-text assessment in a ‘Characteristics of excluded studies’ table.
Multiple publications from the same study will be included only
once. If one of the review authors has contributed to a study, that
author will not take part in reviewing the relevant manuscript or
extracting data from the study. There will be no language restric-
tions and where possible articles will be translated. We will use
Covidence software to screen titles and abstracts identified in our
search, provide reasons for exclusions and generate a flow diagram
(Covidence 2016).
Data extraction and management
Two review authors (GJ and AB) will independently extract data
from the included studies and enter this information into a data
extraction form using Covidence, then import the data into Re-
view Manager 5 (RevMan 5) (RevMan 2014). We will pilot test a
standardised data extraction form andmodify it accordingly before
use. Information collected will include study design, participants,
setting, type of mammography, interval between screenings; num-
ber of screening rounds; duration of screening; co-interventions;
adherence to screening; number of cancers identified, follow-up
(including data sources, completeness, time frames, and sub-group
analysis based on follow-up), management of lead time, calcula-
tion of overdiagnosis; sources of funding and other data relevant
to the ‘Risk of bias’ assessments. We will resolve any discrepancies
by consensus or, if we cannot agree, by consulting a third review
author (KB). For those studies with more than one publication,
we will extract data from all publications, with the most recent
version considered as the primary reference.
Assessment of risk of bias in included studies
Two review authors (GJ and AB) will independently assess and
judge the risk of bias for each included study. We will resolve any
disagreements by discussion. Randomised controlled trials iden-
tified from the searches will be independently assessed for risk of
bias using the Cochrane ‘Risk of bias’ tool (Higgins 2011).We will
assess six forms of bias: selection, performance, attrition, detec-
tion, reporting and other types of bias. We will judge relevant trial
characteristics as at low or high risk of bias following the guidelines
outlined in Higgins 2011. If there is insufficient information to
permit judgement, we will classify the domain as at ‘unclear risk’.
Wewill independently evaluate non-randomised studies and judge
them according to the Risk Of Bias In Non-randomised Studies -
of Interventions (ROBINS-I) tool (Sterne 2016). We will address
the eight bias domains outlined in ROBINS-I, including con-
founding, departures from intended interventions, missing data,
selection of participants into the study, classification of interven-
tions, measurement of outcomes, selection of the reported results
and other types of bias. We will use the guidelines in ROBINS-
I to classify the risk of bias as low, moderate, serious, or critical.
If there is insufficient information to permit judgement, we will
classify the domain as ‘no information’.
Potential confounding factors when estimating overdiagnosis in-
clude:
• age;
• geographical location;
• socioeconomic factors;
• difference in baseline breast cancer incidence trends
between groups;
• reproductive factors;
• hormone replacement therapy (HRT);
• postmenopausal obesity;
• alcohol consumption; and
• competing mortality risk from causes of death other than
breast cancer.
Other biases
Two key areas that have been identified with risk of bias specific to
studies estimating overdiagnosis are: (i) approaches used to obtain
an unscreened comparator group and (ii) methods used to adjust
for lead-time (Biesheuvel 2007).We will assess risk of bias (i) using
existing tools as outlined above, and (ii) using our classification
outlined below.
Lead time bias
Screening studies that do not allow for lead time overestimate
overdiagnosis (Duffy 2008; Puliti 2012). The advance in time of
cancer diagnosis due to screening (lead time) causes a temporary
increase in cancer incidence. Once screening stops, the rate of
detection of cancers in the previously screened group should be
less than the unscreened group, compensating for the earlier in-
crease in incidence due to lead time. This phenomenon is called
the “compensatory drop”. Eventually, if follow-up is longer than
the distribution of lead times, the cumulative incidence in the two
groups will increase at the same rate. Thus, to provide an unbi-
ased estimate of overdiagnosis, there must be an allowance for the
increase in incidence observed during the active screening period.
Importantly, as Baker 2014 points out, lead time only relates to
cancers that were destined to become symptomatic (progressive
pre-clinical cancers). This is because the definition of lead time
requires cancer to present clinically due to symptoms in the ab-
sence of screening. Thus an overdiagnosed cancer does not have a
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lead time (alternatively, we can think of overdiagnosis as having an
infinite lead time because it will never cause symptoms) Gøtzsche
2012.
Methodology for dealing with lead time is diverse and complex,
especially in non-randomised studies (Baker 2014; Duffy 2008;
Etzioni 2014; Gøtzsche 2009; Puliti 2012; Ripping 2017; Zahl
2014), but three main methods exist:
• compensatory drop method: long-term follow-up of
incidence after screening stops to capture and allow for the
effects of lead time (compensatory drop, also called “excess
incidence”, which includes cumulative incidence and early- vs
advanced-stage methods); and
• statistical adjustment: using estimates of average lead time
(and its distributions) from the literature to adjust for lead time;
and
• steady state method: comparison of incidence (total or
stage-specific incidence) in invited and control populations once
screening has been established longer than the expected lead time
(screening is in a “steady state”).
The compensatory dropmethod is the preferred approach and has
beenused in randomised controlled trials (Miller 2014;Zackrisson
2006). Ecological and cohort studies of similar groups of screened
and unscreened women that include cancers diagnosed both dur-
ing the active screening period and after screening has stopped, also
allow for lead time as they capture the compensatory drop. Many
observational studies, however, use alternative methods or simply
do not allow for lead time. Statistical adjustments may contribute
to biased results because the magnitude of lead time is contested
(Duffy 2013; Zahl 2014), and the distributions mostly unknown
(Carter 2015; Davidov 2004). Estimates of mean lead time for
breast cancer range from one to 3.3 years (Duffy 2008; Feinleib
1969; Jonsson 2005; Walter 1983; Zahl 2013), though estimates
based on progressive preclinical cancers only are shorter, at around
one year (Zahl 2013). Only a small percentage of breast cancer
cases have been estimated to have a preclinical duration longer
than five years (Shen 2001; Walter 1983; Zahl 2013). While in-
cidence rates in screened women seem to return to the expected
(control) rates within five years after screening stops (Miller 2014;
Zahl 2012), we need to capture the full distribution of lead time,
including the occasional progressive pre-clinical breast cancer with
a lead time that is long. Lastly, when estimating overdiagnosis, the
management of lead time should reflect individuals time prefer-
ences - women are likely to value more immediate consequences of
overdiagnosis (e.g. harms experiencedwithin the first few years fol-
lowing screening) differently to consequences that may occur well
into the future (harms that occur 15 years after screening) - known
as temporal discounting of future health outcomes (Drummond
2015). Therefore, for both randomised and non-randomised stud-
ies, we will classify lead time bias as outlined in Table 1.
Measures of treatment effect
For dichotomous outcomes (that is, breast cancer cases detected),
we will use the extracted data from the original studies for both
screened and unscreened groups to estimate cumulative incidence
of newly diagnosed breast cancer, or annual incidence of newly
diagnosed breast cancer, or both. We will then calculate the per-
centage risk of overdiagnosis with 95% confidence intervals. Any
method that attempts to measure the percentage of overdiagno-
sis attributable to screening mammography should use the excess
cancers allowing for lead time in the numerator of the percentage
calculation.
Primary outcomea
• Percentage risk of overdiagnosis of all breast cancers
detected in women who are invited to or participate in screening
= (cumulative incidence in the screened group − cumulative
incidence in the control group)/ total number of all breast cancers
detected in screened women during the active screening period).
We will use a binomial distribution when calculating the variance
(Baker 2014; Independent UK Panel on Breast Screening 2012).
When conducting a meta-analysis of overdiagnosis it is impor-
tant to carefully consider the denominator. Including cancers diag-
nosed after screening ends in the denominator dilutes the estimate
of overdiagnosis, makes it dependent on the length of follow-up
(Carter 2015), and does not reflect the value women may place on
more immediate outcomes. Furthermore, the denominator should
include screen-detected, interval and clinically detected breast can-
cers found in women who participate in screening for two reasons.
Firstly, the ratio of screen to interval cancer detection increases as
the time between the screening interval decreases. Thus excluding
interval breast cancers provides an estimate of overdiagnosis that
is dependent on screening frequency and applicable only to one
particular programme. As different studies use different screening
intervals, we need to account for this. This issue was identified
by the Independent UK Panel on Breast Screening 2012, and un-
derpins their view that this expression of overdiagnosis is the best
way to present information to women who are considering partic-
ipation in screening. Secondly, excluding some cancer cases from
the screened group in randomised controlled trials may introduce
selection bias, as those women who do not attend screening but
in whom a cancer is diagnosed may differ with regards to breast
cancer risk and detection rates compared to those women who do
attend screening and receive a breast cancer diagnosis.
Estimates of overdiagnosis should include invasive breast cancer
as well as DCIS, as DCIS is primarily detected by mammography
and currently treated as cancer.
The percentage risk of overdiagnosis, regardless of method, cannot
be directly compared to estimates of breast cancermortality benefit
such as relative risk. Both estimates must be converted to absolute
numbers in order to provide a fair and standardised comparison.
Footnote
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aThe methodology we will use to calculate overdiagnosis is based
on randomised controlled trials, where the intervention is an in-
vitation to screening. Some non-randomised studies compare at-
tenders versus non-attenders. Both lead-time and overdiagnosis
will be smaller in an invited group compared to groups based on
women who actually attend screening. The attenuation of the es-
timate in invited groups depends on the proportion of non-at-
tenders. We will make estimates comparable between invited and
screened groups by deattenuating trial results (Jacklyn 2016).
Secondary outcomes
• Relative risk: the ratio of cumulative incidence in the
screened group to the cumulative incidence in the control group.
• Absolute risk of overdiagnosis = (cumulative incidence in
the screened group − cumulative incidence in the control
group)/ total number of women who are invited to screening).
This will be expressed as a natural frequency for every 1000women
screened.Wewill use a binomial distribution when calculating the
variance.
• Percentage risk of overdiagnosis of screen-detected breast
cancers = (cumulative incidence in the screened group −
cumulative incidence in the control group)/ screen-detected
breast cancers).
When calculating the variance of the percentage risk of overdiag-
nosis as a proportion of screen-detected breast cancers, the numer-
ator includes the cumulative number of clinically detected cancers
in the screened group which are not part of the denominator. To
allow for the variability in the cumulative number of clinically
detected cancers in the screened group we will compute bootstrap
confidence intervals or asymptotic variances assuming the vari-
ables follow independent Poisson distributions.
• Long-term percentage risk of overdiagnosis = (cumulative
incidence in the screened group − cumulative incidence in the
control group)/ cancers diagnosed over the entire follow-up
period in screened women)
We will use a binomial distribution when calculating the variance
(Independent UK Panel on Breast Screening 2012).
• The effect of screening mammography on the incidence of
early- and advanced-stage breast cancer.
◦ We will use summary staging Young 2001 to classify
cancer into one of four main categories:
⋄ DCIS: abnormal cells are contained in the lining
of the breast duct but have not spread to nearby tissue;
⋄ localised: cancer is limited to the tissue of origin
in which it began (primary site) with no evidence of spread;
⋄ regional: cancer has spread beyond the primary
site to nearby lymph nodes, tissues, or organs; and
⋄ distant metastases: cancer has spread beyond the
primary site to distant parts of the body.
◦ We will calculate:
⋄ absolute increase in incidence of DCIS and
localised breast cancer per 100,000 women in a screened
population; and
⋄ absolute decrease in regional and distant
metastases per 100,000 women in a screened population.
◦ We will use one or more comparator populations:
⋄ current unscreened populations;
⋄ historical unscreened populations; or
⋄ younger or older unscreened populations, or
both.
Wewill also examine trends in incidence rates of early-stage (DCIS
or localised disease, summary stage I or II) and advanced-stage
(regional or distant metastases, summary stage III or IV) breast
cancer before and after implementation of screening.
Unit of analysis issues
If studies that incorporate clustering in their design are found, we
will contact the study authors to try and obtain cluster specific
counts from which we will calculate variances (adjusted for clus-
tering). If these data are not available, we will apply the intraclass
correlation coefficients estimated from the studies with available
data to adjust the variances. If none of the clustered studies have
cluster-specific data available thenwe will conduct sensitivity anal-
yses assuming a range of intraclass correlation coefficients.
Dealing with missing data
If possible we will perform intention-to-screen analyses for ran-
domised controlled trials by including all randomised women.
When necessary we will contact authors of publications to ensure
the completeness of data. If data remain unavailable, we will try to
estimate the missing data using the available information. Where
data are missing, we will assume that participants with missing
data did not receive a breast cancer diagnosis. We will report the
proportion of participants with missing outcome data and con-
sider the potential impact of the missing data in our interpretation
of the results.
For non-randomised studies we will exclude participants with
missing data and perform a complete-case analysis. We will report
the proportion of participants withmissing outcome data and con-
sider the potential impact of the missing data in our interpretation
of the results.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity before
any meta-analyses are preformed and judge whether results can
be pooled. We will discuss and assess inconsistency across studies
by visual inspection of the forest plots and, when relevant, assess
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statistical heterogeneity by calculating the I2 statistic with 95%
confidence intervals (Higgins 2003). If the I2 statistic is greater
than 30%, we will explore causes of heterogeneity in sensitivity
and subgroup analyses. We will not perform meta-analyses if we
encounter unexplained heterogeneity that would give misleading
results. Given the clinical and methodological diversity of non-
randomised studies, we will conduct any meta-analyses using a
random-effects model. We will consider using meta-regression if
there are more than 10 studies in the meta-analysis.
Assessment of reporting biases
We will assess reporting bias, especially publication bias and out-
come reporting bias, according to the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We will explore publication bias by producing funnel plots
and using Egger’s test (Egger 1997). We will visually inspect the
funnel plot if there are more than 10 studies in the meta-analysis.
Data synthesis
We will conduct separate meta-analyses (if appropriate) for ran-
domised controlled trials and non-randomised studies. If re-analy-
sis of the data provided by randomised controlled trials is required,
we will perform an intention-to-screen analyses by including all
randomised women invited to screening. Analysis by intention-
to-screen will underestimate any real effect in women who attend
screening. Thus, as a secondary analysis we will adjust the primary
outcome measure for adherence to screening in individual trials
using a previously published method (Jacklyn 2016). Essentially,
this method divides the intention-to-screen effect by the propor-
tion attending screening. To allow for heterogeneity wewill use the
DerSimonian and Laird random-effects method and will present
95% confidence intervals for both the intention-to-treat and ad-
justed estimates (DerSimonian 1986). In case of heterogeneity in
the trial results (P < 0.10), we will explore possible causes. We
will perform the analysis using RevMan 5 (RevMan 2014), and
Microsoft Excel. For the cumulative and deattenuated meta-anal-
yses, we will develop a spreadsheet and perform statistical analyses
using Microsoft Excel software.
If clinical heterogeneity is not excessive in the non-randomised
studies and pooling results is appropriate, then we will perform
a meta-analysis using the DerSimonian and Laird random-effects
method (DerSimonian 1986), using RevMan 5 (RevMan 2014).
In order to observe changes in screeningmammography and trends
in overdiagnosis we will also conduct a cumulative meta-analysis
(Lau 1992). We will add studies one at a time in order of the date
of the active screening period and will summarise the results as
each new study is included. For the cumulative meta-analyses, we
will develop a spreadsheet and perform statistical analyses using
Microsoft Excel software.
If it is possible to combine results, we will analyse and present the
pooled estimates according to study design.Wewill stratify studies
according to risk of bias and present three (stratified) analyses of
the intervention effect incorporating:
• all studies;
• those at low or moderate risk of bias; and
• those at serious, critical or high risk of bias.
We will draw forest plots to display results across studies according
to risk of bias, key study design features and date of the active
screening period. In the event of important heterogeneity, we will
not pool data across non-randomised studies and instead will pro-
vide a narrative review and present individual study findings in a
summary table according to study design.
We will use the GRADE approach to assess the quality of the ev-
idence for overdiagnosis separately for randomised and non-ran-
domised studies if appropriate.Wewill useGRADEproGDT soft-
ware, GRADEproGDT 2015, and create a ‘Summary of findings’
table (GRADE Working Group 2004). Given the vast difference
in quality of evidence the analysis by study type is likely to have,
it may prove inappropriate to provide an overall assessment of the
quality of the body of evidence.
Subgroup analysis and investigation of heterogeneity
If data are sufficient we will perform subgroup analyses by:
• age at intervention (age groups 40 to 49 years, 50 to 69
years, and ≥ 70 years);
• study design;
• country or geographical region of study;
• date of active screening period; and
• frequency of screening (screening interval).
Sensitivity analysis
If meta-analyses are feasible, we will conduct sensitivity analyses to
determine whether findings are sensitive to decisions made during
the review process such as our assessment of the level of clinical
heterogeneity.Wewill evaluate themethods used tohandlemissing
data by excluding these studies in a sensitivity analysis, and we will
discuss the extent to which the missing data are likely to influence
the results of the study.
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A D D I T I O N A L T A B L E S
Table 1. Judgement of the risk of lead time bias in randomised and non-randomised studies that estimate overdiagnosis
Risk of bias Criteria Justification
Low Management of lead time was based on a comparison
of cumulative incidence in a screened and unscreened
population after an ideal follow-up time after screening
stops (≥ 10 years)
Carter 2015
Moderate Management of lead time was based on a comparison of
cumulative incidence in a screened and unscreened pop-
ulation after a sufficient follow-up time after screening
stops (5 to 9 years)
Biesheuvel 2007; Miller 2014; Puliti 2011; Shen 2001;
Walter 1983; Zahl 2012
Serious Management of lead time was based on:
• a statistical correction using directly observed data
and a sufficient mean lead time; or
• a statistical correction from a model which
explicitly allowed for progressive and non-progressive
preclinical cancers, and competing mortality.
Baker 2014; Zahl 2013
Critical Management of lead time was based on:
• an insufficient follow-up time after screening
stops (< 5 years); or
• a statistical correction from a model that did not
allow for progressive and non-progressive cancer, and
competing mortality; or
Baker 2014; Zahl 2013
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Table 1. Judgement of the risk of lead time bias in randomised and non-randomised studies that estimate overdiagnosis
(Continued)
• no consideration of lead time.
No information Insufficient information on which to base a judgement
about the risk of lead time bias
A P P E N D I C E S
Appendix 1. Excluded study types
Excluded study types Reason for exclusion
Systematic reviews that only report or combine quantitative es-
timates of other included study types (randomised trials, cohort
studies, case-control studies and ecological studies) that quanti-
fied overdiagnosis
Systematic reviewswill be excluded if they simply summarise stud-
ies that had each quantified overdiagnosis (for example, by com-
bining data from several estimates of overdiagnosis)
Non-systematic reviews A review of the literature that does not adhere to a protocol is sub-
ject to substantial biases and limitations and therefore insufficient
for clinical decision making
Modelling studies Modelling studies are useful for addressing research questions
where direct evidence is difficult to obtain, such as with cancer
screening, where the data collected or duration of follow-up may
be limited. Models that aim to quantify overdiagnosis may at-
tempt to simulate disease progression and outcomes in screened
and unscreened populations. They are based on data fromprimary
or secondary studies and can use multiple other data sources, or
assumptions to extrapolate beyond the observed data. It is chal-
lenging to create valid and reliable models of cancer screening
that estimate overdiagnosis due to key uncertainties in the avail-
able data, particularly with respect to the proportion of preclinical
cancers which are non-progressive (Mandelblatt 2015). Further,
calculation of overdiagnosis requires an estimate of the mean du-
ration of lead time and the shape of the lead time distribution.
Because lead time is unobservable in practice, assumptions have
to be made, without ever being able to validate them fully (Savage
2010). As the rate of overdiagnosis is implicit in the lead time
distribution assumptions of the model - particularly the tail shape
of the lead time distribution and non-progressive lesions which
have an infinite lead time (Baker 2014) - overdiagnosis cannot be
13Overdiagnosis due to screening mammography for women aged 40 years and over (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
estimated frommodels. For this reason, we will exclude modelling
studies from our systematic review
Pathological or imaging studies Studies that examine overdiagnosis resulting fromnon-progressive
disease underestimate total overdiagnosis as they cannot account
for overdiagnosis due to competing mortality
Appendix 2. MEDLINE (via OvidSP)
1 Breast Neoplasms/dg [Diagnostic Imaging]
2 exp Mammography/
3 mammogra$.tw.
4 1 or 2 or 3
5 exp Mass Screening/
6 Breast Neoplasms/pc [Prevention & Control]
7 (screen$ or (routine$ adj3 (test$ or check$ or diagnos$ or detect$))).tw
8 exp “Early Detection of Cancer”/
9 (early adj3 (detect$ or diagnos$)).tw.
10 5 or 6 or 7 or 8 or 9
11 exp Medical Overuse/
12 diagnostic errors/
13 False Positive Reactions/
14 (overdiagnos$ or overdetect$ or overtest$ or over-diagnos$ or over-detect$ or over-test$).tw
15 inciden$.tw.
16 11 or 12 or 13 or 14 or 15
17 4 and 10 and 16
18 exp Breast Neoplasms/
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(Continued)
19 (breast adj6 cancer$).tw.
20 (breast adj6 neoplasm$).tw.
21 (breast adj6 carcinoma$).tw.
22 (breast adj6 tumo?r$).tw.
23 or/18-22
24 17 and 23
25 remove duplicates from 24
26 Animals/ not Humans/
27 25 not 26
Appendix 3. Embase (via OvidSP)
1 exp breast/
2 exp breast disease/
3 (1 or 2) and exp neoplasm/
4 exp breast tumor/
5 exp breast cancer/
6 exp breast carcinoma/
7 (breast$ adj5 (neoplas$ or cancer$ or carcin$ or tumo$ or metasta$ or malig$)).ti,ab
8 or/3-7
9 exp mammography/
10 mammogra$.tw.
11 9 or 10
12 breast cancer/pc [Prevention]
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(Continued)
13 mass screening/
14 cancer screening/
15 (screen$ or (routine$ adj3 (test$ or check$ or diagnos$ or detect$))).tw
16 early diagnosis/
17 early cancer diagnosis/
18 (early adj3 (detect$ or diagnos$)).tw.
19 or/12-18
20 exp diagnostic error/
21 (overdiagnos$ or overdetect$ or overtest$ or over-diagnos$ or over-detect$ or over-test$).tw
22 inciden$.tw.
23 20 or 21 or 22
24 8 and 11 and 19 and 23
25 remove duplicates from 24
26 limit 25 to (human and embase)
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